Management of hypertensive disorders in pregnancy

Women's Health

Volumn 10, Issue 4, 2014, Pages 385-404

  Moussa, Hind N ^a   Arian, Sara E ^a   Sibai, Baha M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

eclampsia; HELLP syndrome; hypertension; pre eclampsia; pregnancy; severe features

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BLOOD PRESSURE MEASUREMENT; CESAREAN SECTION; CHRONIC HYPERTENSION; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MILK LEVEL; ECLAMPSIA; EVIDENCE BASED MEDICINE; FEMALE; FETAL PROGRAMMING; FETUS ECHOGRAPHY; FETUS MONITORING; FETUS RISK; FOLLOW UP; FUNCTION TEST; HELLP SYNDROME; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; INTRAPARTUM CARE; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; MATERNAL HYPERTENSION; MEDICAL HISTORY; MEDICAL TERMINOLOGY; NONHUMAN; NONSTRESS TEST; PATIENT MONITORING; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL CARE; PUERPERIUM; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SODIUM RESTRICTION; SUPERIMPOSED PREECLAMPSIA; SUPERIMPOSED PREECLAMPSIA WITH SEVERE FEATURE; TREATMENT INDICATION; VAGINAL DELIVERY; WEIGHT REDUCTION; HYPERTENSION, PREGNANCY-INDUCED; INCIDENCE; PRE-ECLAMPSIA; PREGNANCY; SEVERITY OF ILLNESS INDEX;

ANTIHYPERTENSIVE AGENTS; FEMALE; FETAL MONITORING; HELLP SYNDROME; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; INCIDENCE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; SEVERITY OF ILLNESS INDEX;

EID: 84907518283     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.14.32     Document Type: Review

References (68)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
2. Sullivan SD, Umans JG, Ratner R. Hypertension complicating diabetic pregnancies: pathophysiology, management, and controversies. J. Clin. Hypertens. (Greenwich) 13(4), 275-284 (2011).
3. Sibai BM. Diagnosis and management of gestational hypertension and pre-eclampsia. Obstet. Gynecol. 102(1), 181-192 (2003).
4. Coppage KH, Sibai BM. Management of pre-eclampsia remote from term. Postgrad. Obstet. Gynecol. 23(14), 1-8 (2003).
5. Roberts JM, Pearson GD, Cutler JA, Lindheimer MD. Summary of the NHLBI Working Group on research on hypertension during pregnancy. Hypertens. Pregnancy 22(2), 109-127 (2003).
6. Labarthe D, Ayala C. Nondrug interventions in hypertension prevention and control. Cardiol. Clin. 20(2), 249-263 (2002).
7. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of Type 2 diabetes in youth. Diabetes Care 22(2), 345-354 (1999).
8. Berg CJ, Atrash HK, Koonin LM, Tucker M. Pregnancy-related mortality in the United States, 1987-1990. Obstet. Gynecol. 88(2), 161-167 (1996).
9. Callaghan WM, Berg CJ. Pregnancy-related mortality among women aged 35 years and older, United States, 1991-1997. Obstet. Gynecol. 102(5), 1015-1021 (2003).
10. Gifford RW, August PA, Cunningham G, et al. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am. J. Obstet. Gynecol. 183(1), S1-S22 (2000).
11. NICE. The management of hypertensive disorders during pregnancy, Clinical guidelines CG107. August 2010. www.nice.org.uk/guidance/cg107
12. Brown MA, Lindheimer MD, Swiet Md, Assche AV, Moutquin J-M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens. Pregnancy 20(1), IX-XIV (2001).
13. Williams D. Long-term complications of pre-eclampsia. Semin. Nephrol. 31(1), 111-122 (2011).
14. Stone P, Cook D, Hutton J, Purdie G, Murray H, Harcourt L. Measurements of blood pressure, oedema and proteinuria in a pregnant population of New Zealand. Aust. N. Z. J. Obstet Gynaecol. 35(1), 32-37 (1995).
15. Fox NS, Huang M, Chasen ST. Second-trimester fetal growth and the risk of poor obstetric and neonatal outcomes. Ultrasound Obstet. Gynecol. 32(1), 61-65 (2008).
16. Morikawa M, Yamada T, Cho K, Yamada H, Sakuragi N, Minakami H. Pregnancy outcome of women who developed proteinuria in the absence of hypertension after mid-gestation. J. Perinat. Med. 36(5), 419-424 (2008).
17. Roberts JM, August PA, Bakris G, et al. Hypertension in pregnancy report of the American College of Obstetricians and Gynecologists Task Force on hypertension in pregnancy. Obstet. Gynecol. 122(5), 1122-1131 (2013).
18. Duley L, Henderson-Smart DJ, Walker GJ, Chou D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst. Rev. 8, 12 (2010).
19. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet. Gynecol. 103(5 Pt 1), 981-991 (2004).
20. Sibai BM, Gordon T, Thom E, et al. Risk factors for pre-eclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am. J. Obstet. Gynecol. 172(2 Pt 1), 642-648 (1995).
21. Sibai BM. Chronic hypertension in pregnancy. Obstet. Gynecol. 100, 369-377 (2002).
22. Bulletins ACoP. ACOG Practice Bulletin. Chronic hypertension in pregnancy. ACOG Committee on Practice Bulletins. Obstet. Gynecol. 98(1), 177-185 (2001).
23. Vanek M, Sheiner E, Levy A, Mazor M. Chronic hypertension and the risk for adverse pregnancy outcome after superimposed pre-eclampsia. Int. J. Gynaecol. Obstet. 86(1), 7-11 (2004).
24. Zetterstrom K, Lindeberg SN, Haglund B, Hanson U. Maternal complications in women with chronic hypertension: a population-based cohort study. Acta. Obstet. Gynecol. Scand. 84(5), 419-424 (2005).
25. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am. J. Obstet. Gynecol. 171(2), 410-416 (1994).
26. Sibai BM, Lindheimer M, Hauth J, et al. Risk factors for pre-eclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. N. Engl. J. Med. 339(10), 667-671 (1998).
27. Williams MA, Mittendorf R, Monson RR. Chronic hypertension, cigarette smoking, and abruptio placentae. Epidemiology 2(6), 450-453 (1991).
28. Ananth CV, Savitz DA, Bowes WA, Luther ER. Influence of hypertensive disorders and cigarette smoking on placental abruption and uterine bleeding during pregnancy. Br. J. Obstet. Gynaecol. 104(5), 572-578 (1997).
29. Ferrer RL, Sibai BM, Mulrow CD, Chiquette E, Stevens KR, Cornell J. Management of mild chronic hypertension during pregnancy: a review. Obstet. Gynecol. 96(5 Pt 2), 849-860 (2000).
30. Griffith J, Conway DL. Care of diabetes in pregnancy. Obstet. Gynecol. Clin. North. Am. 31(2), 243-256 (2004).
31. Coustan DR. Gestational diabetes. Diabetes Care 16(3), 8-15 (1993).
32. Weir MR. Differing effects of antihypertensive agents on urinary albumin excretion. Am. J. Nephrol. 16(3), 237-245 (1996).
33. Sibai BM, Abdella TN, Anderson GD. Pregnancy outcome in 211 patients with mild chronic hypertension. Obstet. Gynecol. 61(5), 571-576 (1983).
34. ACOG Educational Bulletin. Special problems of multiple gestation. Number 253, November 1998 (Replaces Number 131, August 1989). American College of Obstetricians and Gynecologists. Int. J. Gynaecol. Obstet. 64(3), 323-333 (1999).
35. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, Group PC. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369(9575), 1791-1798 (2007).
36. National Collaborating Centre for Womens and Childrens Health (UK). Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. (RCOG Press, London (2010 Aug). NICE Clinical Guidelines, No. 107. www.ncbi.nlm.nih.gov/books/NBK62652
37. Sibai BM. Management of late preterm and early-term pregnancies complicated by mild gestational hypertension/pre-eclampsia. Semin. Perinatol. 35(5), 292-296 (2011).
38. Publications Committee, Society for Maternal-Fetal Medicine, Sibai BM. Evaluation and management of severe pre-eclampsia before 34 weeks gestation. Am. J. Obstet. Gynecol. 205(3), 191-198 (2011).
39. Blackwell SC, Redman ME, Tomlinson M, et al. Labor induction for the preterm severe pre-eclamptic patient: is it worth the effort? J. Matern. Fetal. Med. 10(5), 305-311 (2001).
40. Alanis MC, Robinson CJ, Hulsey TC, Ebeling M, Johnson DD. Early-onset severe pre-eclampsia: induction of labor vs elective cesarean delivery and neonatal outcomes. Am. J. Obstet. Gynecol. 199(3), 262.e1-6 (2008).
41. Sibai BM. Etiology and management of postpartum hypertension-pre-eclampsia. Am. J. Obstet. Gynecol. 206(6), 470-475 (2012).
42. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. 24(1), CD002252 (2007).
43. Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet. Gynecol. 67(4), 517-522 (1986).
44. Zetterström K, Lindeberg SN, Haglund B, Hanson U. The association of maternal chronic hypertension with perinatal death in male and female offspring: a record linkage study of 866,188 women. BJOG 115(11), 1436-1442 (2008).
45. Sibai BM. Hypertension in pregnancy: tailoring treatment to risk. OBG Management 15(7), 58-68 (2003).
46. Magee LA, Abalos E, von Dadelszen P, et al. How to manage hypertension in pregnancy effectively. Br. J. Clin. Pharmacol. 72(3), 394-401 (2011).
47. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst. Rev. 19(3), CD001449 (2006).
48. Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol. 31(1), 70-85 (2011).
49. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 3, CD002863 (2003).
50. Davis BR, Cutler JA, Furberg CD, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Ann. Intern. Med. 137(5 Pt 1), 313-320 (2002).
51. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am. J. Obstet. Gynecol. 162(4), 960-966 (1990).
52. Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam SS. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am. J. Obstet. Gynecol. 168(1 Pt 1), 152-156 (1993).
53. Sibai BM, Barton JR, Akl S, Sarinoglu C, Mercer BM. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of pre-eclampsia remote from term. Am. J. Obstet. Gynecol. 167(4 Pt 1), 879-884 (1992).
54. Lindow SW, Davies N, Davey DA, Smith JA. The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. Br. J. Obstet. Gynaecol. 95(12), 1276-1281 (1998).
55. Rizzo G, Arduini D, Mancuso S, Romanini C. Effects of nifedipine on umbilical artery velocity waveforms in healthy human fetuses. Gynecol. Obstet. Invest. 24(3), 151-154 (1987).
56. Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am. J. Obstet. Gynecol. 174(3), 823-828 (1996).
57. Koukoulas I, Mustafa T, Douglas-Denton R, Wintour EM. Angiotensin II receptor (type 1 and 2) expression peaks when placental growth is maximal in sheep. Am. J. Physiol. Regul. Intefr. Comp. Physiol. 283(4), R972-R982 (2002).
58. Langer O, Langer N. Diabetes in women older than 40 years of age. Social and medical aspects. Obstet. Gynecol. Clin. North Am. 20(2), 299-311 (1993).
59. Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ. Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch. Dis. Child Fetal Neonatal. Ed. 92(5), F402-403 (2007).
60. Li DK, Yang CM, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 343, d5931 (2011).
61. How HY, Sibai BM. Use of angiotensin-converting enzyme inhibitors in patients with diabetic nephropathy. J. Matern. Fetal Neonatal Med. 12(6), 402-407 (2002).
62. Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 350(9089), 1446-1447 (1997).
63. Kirk JK. Angiotensin-II receptor antagonists: their place in therapy. Am. Acad. Family Physicians 59(11), 3140-3148 (1999).
64. Kaplan NM. Angiotensin II receptor antagonists in the treatment of hypertension. Am. Acad. Family Physicians 60(4), 1185-1190 (1999).
65. Redman CW, Sargent IL. Latest advances in understanding pre-eclampsia. Science 308(5728), 1592-1594 (2005).
66. Thadhani R, Kisner T, Hagmann H, et al. Pilot Study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in pre-eclampsia. Circulation 124(8), 940-950 (2011).
67. Barker DJP, Eriksson JG, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int. J. Epidemiol. 31(6), 1235-1239 (2002).
68. Barton JR, Sibai BM.Prediction and prevention of recurrent pre-eclampsia. Obstet. Gynecol. 112(2 Pt 1), 359-372 (2008).